The U.S. Food and Drug Administration (FDA) said it has cleared RIS/PACS vendor Infinitt North America's fusion software for marketing in North America.
Infinitt's Xelis Fusion package can be used with the company's Web-based PACS or as a standalone product, allowing any third-party PACS user to query, view, and analyze studies from any DICOM database to perform fusion of CT, PET, and MR images, according to the firm.
The software offers both automatic and manual registration methods, quantitative analysis tools, and image navigation; supports 3D region-of-interest analysis; calculates PET standardized uptake values; and stores and sends the fused images in DICOM 3.0 format, Infinitt said.
